Back to mobile site

Alnylam Pharmaceuticals (ALNY) Reiterated at Neutral by Cantor Fitzgerald Amid Exciting Pipeline Inbounds

September 30, 2026 6:58 AM EDT Send to a Friend
Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating and $325.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login